Dishman Carbogen Amcis Quarterly Results for Trading Insights
In Sept 2025, Dishman Carbogen Amcis (DCAL) reported revenue ₹661 Cr and net profit ₹65 Cr — revenue -17.0% YoY. Compare with DCAL stock valuation models to assess whether the stock is under or overvalued.
DCAL Quarterly Results — Revenue, Profit & EPS Highlights
Dishman Carbogen Amcis latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore DCAL share price data to track price trends across different timeframes.
- Revenue of ₹661 Cr in Sept 2025 (-8.7% vs Mar 2025, -17.0% vs Sept 2024)
- Net Profit of ₹65 Cr in Sept 2025 (+51.2% vs Mar 2025, +97.0% vs Sept 2024)
- EBITDA of ₹157 Cr in Sept 2025 (+5.4% vs Mar 2025)
- Operating Margin of 23.0% in Sept 2025 (+3.0pp vs Mar 2025)
- Earnings Per Share of ₹4.16 in Sept 2025 (+51.3% vs Mar 2025)
Dishman Carbogen Amcis Quarterly Results — Revenue, EBITDA, Net Profit & EPS
DCAL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 661 | 724 | 733 | 727 | 796 | -8.7% | -17.0% |
| Net Profit (₹ Cr) | 65 | 43 | 23 | -13 | 33 | - | - |
| EBITDA (₹ Cr) | 157 | 149 | 163 | 120 | 151 | - | - |
| EPS (₹) | 4.16 | 2.75 | 1.49 | -0.83 | 2.11 | - | - |
| Operating Margin (%) | 23.0% | 20.0% | 19.0% | 16.0% | 18.0% | - | - |
DCAL Share Price Trend — 1-Year Movement Across Quarterly Results
Dishman Carbogen Amcis 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit DCAL share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
DCAL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Dishman Carbogen Amcis latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹443,373.10 Cr | 1824.8 | 14,875 | 3,125 | +10.8% | - | 21.0% | 140.4 |
|
Divis Laboratories
Sept 2025 |
₹178,235.60 Cr | 6796.0 | 2,860 | 689 | +7.1% | - | 24.1% | 261.7 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹145,389.39 Cr | 4295.8 | 3,219 | 591 | +11.3% | - | 18.4% | 244.9 |
|
Cipla
Mar 2026 |
₹107,240.96 Cr | 1327.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 193.2 |
|
Dr Reddys Laborator…
Mar 2026 |
₹105,607.38 Cr | 1265.3 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 477.5 |
All amounts in ₹ Crores